DK1937827T3 - Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD - Google Patents
Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SODInfo
- Publication number
- DK1937827T3 DK1937827T3 DK06790622.2T DK06790622T DK1937827T3 DK 1937827 T3 DK1937827 T3 DK 1937827T3 DK 06790622 T DK06790622 T DK 06790622T DK 1937827 T3 DK1937827 T3 DK 1937827T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- diagnosis
- prevention
- treatment
- sod
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71240005P | 2005-08-31 | 2005-08-31 | |
PCT/CA2006/001444 WO2007025385A1 (en) | 2005-08-31 | 2006-08-31 | Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1937827T3 true DK1937827T3 (da) | 2012-01-23 |
Family
ID=37808437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06790622.2T DK1937827T3 (da) | 2005-08-31 | 2006-08-31 | Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD |
Country Status (8)
Country | Link |
---|---|
US (2) | US8759029B2 (da) |
EP (1) | EP1937827B1 (da) |
JP (1) | JP5242396B2 (da) |
AT (1) | ATE526345T1 (da) |
CA (1) | CA2620351C (da) |
DK (1) | DK1937827T3 (da) |
ES (1) | ES2374102T3 (da) |
WO (1) | WO2007025385A1 (da) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4668191B2 (ja) | 2003-08-20 | 2011-04-13 | アモールフィックス・ライフ・サイエンシィズ・リミテッド | タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法 |
US7887803B2 (en) | 2005-12-02 | 2011-02-15 | Amorfix Life Sciences | Methods and compositions to treat misfolded-SOD1 mediated diseases |
US7794692B2 (en) | 2005-12-02 | 2010-09-14 | Amorfix Life Sciences Ltd. | Methods and compositions for detecting amyotrophic lateral sclerosis |
EP2502999A3 (en) * | 2006-03-03 | 2013-01-23 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
WO2010056732A1 (en) | 2008-11-12 | 2010-05-20 | Marv Enterprises Llc | Utilization of stents for the treatment of blood borne carcinomas |
US9216386B2 (en) * | 2009-03-17 | 2015-12-22 | Marv Enterprises, LLC | Sequential extracorporeal treatment of bodily fluids |
EP2483407A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
WO2011142461A1 (ja) * | 2010-05-13 | 2011-11-17 | 国立大学法人 東京大学 | 筋萎縮性側索硬化症(als)の診断のための抗体 |
US9109037B2 (en) | 2010-10-26 | 2015-08-18 | University Of Massachusetts | Anti-SOD1 antibodies and uses thereof |
EP3628689A1 (en) | 2010-12-17 | 2020-04-01 | Neurimmune Holding AG | Human anti-sod1 antibodies |
KR20210111242A (ko) | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
WO2023033049A1 (ja) * | 2021-09-02 | 2023-03-09 | 国立大学法人滋賀医科大学 | 筋萎縮性側索硬化症の原因となる変異型sod1タンパク質に結合性を有する抗体及び抗体断片 |
JPWO2023033050A1 (da) * | 2021-09-02 | 2023-03-09 | ||
CN113774089A (zh) * | 2021-10-11 | 2021-12-10 | 深圳大学 | 肌萎缩侧索硬化细胞模型细胞株的构建方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4940659A (en) | 1987-02-20 | 1990-07-10 | Monoclonetics International, Inc. | Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome |
US5843641A (en) | 1993-02-26 | 1998-12-01 | Massachusetts Institute Of Technology | Methods for the daignosis, of familial amyotrophic lateral sclerosis |
US5780489A (en) | 1996-08-21 | 1998-07-14 | Brooks; Benjamin Rix | Method for treating amyotrophic lateral sclerosis |
US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
JP4668191B2 (ja) * | 2003-08-20 | 2011-04-13 | アモールフィックス・ライフ・サイエンシィズ・リミテッド | タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法 |
-
2006
- 2006-08-31 DK DK06790622.2T patent/DK1937827T3/da active
- 2006-08-31 EP EP06790622A patent/EP1937827B1/en active Active
- 2006-08-31 US US12/065,403 patent/US8759029B2/en not_active Expired - Fee Related
- 2006-08-31 JP JP2008528307A patent/JP5242396B2/ja not_active Expired - Fee Related
- 2006-08-31 ES ES06790622T patent/ES2374102T3/es active Active
- 2006-08-31 AT AT06790622T patent/ATE526345T1/de active
- 2006-08-31 WO PCT/CA2006/001444 patent/WO2007025385A1/en active Application Filing
- 2006-08-31 CA CA2620351A patent/CA2620351C/en not_active Expired - Fee Related
-
2014
- 2014-05-27 US US14/288,374 patent/US9266963B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5242396B2 (ja) | 2013-07-24 |
US20140341927A1 (en) | 2014-11-20 |
ES2374102T3 (es) | 2012-02-13 |
WO2007025385A1 (en) | 2007-03-08 |
US20090068194A1 (en) | 2009-03-12 |
US8759029B2 (en) | 2014-06-24 |
CA2620351A1 (en) | 2007-03-08 |
US9266963B2 (en) | 2016-02-23 |
CA2620351C (en) | 2015-04-21 |
ATE526345T1 (de) | 2011-10-15 |
JP2009507475A (ja) | 2009-02-26 |
EP1937827B1 (en) | 2011-09-28 |
EP1937827A4 (en) | 2009-02-18 |
EP1937827A1 (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1937827T3 (da) | Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD | |
LUC00053I9 (fr) | Anticorps diriges contre cd38 pour le traitement du myelome multiple | |
EP4218794A3 (en) | Immunological targeting of pathological tau proteins | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
EA200870050A1 (ru) | Анти-il-17-антитела | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
MX2009005743A (es) | Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab. | |
MA30632B1 (fr) | Anticorps humanisé | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
CA2821268C (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
NO20084650L (no) | Modifiserte humaniserte anti-interleukin-18 antistoffer | |
PH12011502389A1 (en) | Monoclonal antibody | |
PE20100684A1 (es) | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh | |
MX338421B (es) | Anticuerpos fosfoespecificos que reconocen la proteina tau. | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
WO2008150946A8 (en) | HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF | |
TW200709817A (en) | Platform antibody compositions | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
MX2009013503A (es) | Anticuerpo monoclonal anti-amiloide-beta. | |
EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
EA201992688A1 (ru) | Средства, пути применения и способы лечения | |
SG162829A1 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
CR20140496A (es) | Anticuerpos humanizados contra beta-amiloides |